Autologous Natural Killer Cell Injection (E10H)

E10H is an anti‑tumor immunotherapy independently developed by Doublle Biotech (Guangzhou). It is the first autologous NK cell injection in China to enter clinical trials. Phase I study in advanced gastrointestinal tumors has been completed, demonstrating a favorable safety profile.

E10H®

Autologous Natural Killer Cell Injection
Doublle Biotech (Guangzhou) · First‑in‑China autologous NK cell therapy
Phase I Completed Autologous NK Cell Therapy High Safety Profile High Purity & Activity
🎯 Direct tumor cell killing via perforin and granzyme release
🔁 ADCC effect – recognizes specific IgG antibodies on cancer cells
🧬 Induction of apoptosis via FasL and TRAIL pathways
🌿 Secretes chemokines & cytokines (IFN‑γ, TNF‑α) to recruit dendritic cells and activate T cells
🧪 Proven synergy with monoclonal antibodies – enhanced anti‑tumor efficacy
🔬 Indication: Gastrointestinal Tumors (advanced stage)
📞 Contact Us · Request Information

🔬 Mechanism of Action
Multi‑pathway anti‑tumor activity

Click the right image to preview animation

  • Direct killing: Releases perforin and granzyme to eliminate tumor cells
  • Chemokine & cytokine secretion: Recruits dendritic cells, presents antigens, activates T cells; secretes IFN‑γ, TNF‑α
  • ADCC function: Recognizes specific IgG antibodies on cancer cell surfaces
  • Induction of apoptosis: Triggers target cell death via FasL and TRAIL

High Purity NK Cells

NK cell purity data 1 NK cell purity data 2

High Activity NK Cells

NK cell activity assay

Effector:Target ratio = 5:1, Incubation time = 2h

✨ GMP‑compliant manufacturing | Strict quality control | High purity & potency

📊 Preclinical Efficacy
Broad anti‑tumor potential & combination synergy

E10H demonstrates potent anti‑tumor activity through multiple mechanisms. Preclinical studies have shown robust killing efficacy against a wide range of tumors, including but not limited to liver cancer, gastric cancer, and colorectal cancer.

E10H preclinical efficacy data

Combination Advantage: Leveraging its ADCC capability, drug interaction studies reveal that E10H combined with monoclonal antibodies achieves significantly enhanced tumor killing both in vitro and in vivo. Integrating E10H with other treatment modalities offers a novel strategy for cancer therapy.

✅ Phase I clinical trial in advanced gastrointestinal tumors completed
✅ Favorable safety and tolerability confirmed
✅ Novel platform for combination immunotherapy

🏅 First autologous NK cell injection in China to enter clinical development | Broad‑spectrum anti‑tumor potential
✔️ Phase I Completed (Gastrointestinal Tumors) ✔️ First Autologous NK in China ✔️ High Purity & High Activity ✔️ Synergy with Monoclonal Antibodies
*Additional clinical and preclinical data available upon request
© Doublle Biotech (Guangzhou) · Autologous Natural Killer Cell Injection E10H · For medical professionals only
This page is for scientific and product information purposes only, not a substitute for medical advice.